Home/Pipeline/Influenza Program

Influenza Program

Influenza

PreclinicalActive

Key Facts

Indication

Influenza

Phase

Preclinical

Status

Active

Company

Arisan Therapeutics

About Arisan Therapeutics

Arisan Therapeutics is a private, preclinical-stage biotech focused on developing small-molecule antiviral drugs for infectious diseases. The company is targeting high-burden viral infections such as COVID-19 and influenza, operating in a critical and dynamic segment of the pharmaceutical market. As a young company, it is in the early stages of building its pipeline and technology platform, positioning itself to address unmet medical needs in virology. Its success will depend on advancing its research, securing funding, and navigating the complex competitive and regulatory landscape of antiviral drug development.

View full company profile

Therapeutic Areas

Infectious Diseases Virology

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Mimotopes-004	Mimotopes	Preclinical	Active
Next-Gen / Universal Flu Vaccines	CSL Seqirus	Research / Early Clinical	Active
Oseltamivir 75 mg	MSN Laboratories	Commercial	Active
AI Programme - Influenza	Poolbeg Pharma	Discovery	Active - Target/Candidate ID
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active